Decreased risk of breast cancer associated with oral bisphosphonate therapy
Aju Mathew,1 Adam Brufsky,21Department of Internal Medicine, University of Pittsburgh Medical Center, 2Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USAAbstract: Preclinical studies and adjuvant trials using bisphosphonates have fo...
Guardado en:
Autores principales: | Mathew A, Brufsky A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7ba30ee2c0064d89a8d91a7226d0fe49 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
por: Bauer M, et al.
Publicado: (2012) -
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
por: Allan Lipton
Publicado: (2011) -
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Brock Schroeder, et al.
Publicado: (2017) -
Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
por: Mathilde M. M. Almekinders, et al.
Publicado: (2021) -
Does Adjunctive Naturopathic Care Decrease Survival Rates in Breast Cancer Patients?
por: Keith I. Block MD
Publicado: (2021)